Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PD-1 antibody-activated autologous tumor-infiltrating lymphocytes
- Development stage
- Unknown
- Lead developer
- Iovance Biotherapeutics
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**anti-PD-1 antibody-activated TILs-Sun Yat-sen University-colorectal cancer** refers to an experimental autologous cell therapy developed by Sun Yat-sen University. In this approach, tumor-infiltrating lymphocytes (TILs) are harvested from a patient's colorectal tumor, expanded ex vivo, and specifically activated using an anti-PD-1 antibody. This activation step is designed to prevent the exhaustion of T cells by blocking the PD-1/PD-L1 inhibitory pathway, thereby enhancing their cytotoxic potential and anti-tumor activity upon re-infusion. The therapy is currently being evaluated in Phase I/II clinical trials as an adjuvant treatment following chemotherapy for participants with stage III colorectal cancer to assess safety and disease-free survival.
- Other names
- anti-PD1 activated TILsanti-PD-1 activated TILsanti-PD 1 activated TILsanti-PD-1 antibody-activated TILsanti-PD1 antibody-activated TILsanti-PD 1 antibody-activated TILs
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on anti-PD-1 antibody-activated autologous tumor-infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PD-1 antibody-activated autologous tumor-infiltrating lymphocytes.